| 摘要 |
<p>Disclosed is a pharmaceutical composition, preferably in the form of tablets, which comprises, as an active ingredient, from 1 to 90 percent by weight of a physical form of N-[4-[5- -(cyclopentyloxycarbonyl)-amino-1-methylindol-3-yl-methyl]-3- -methoxybenzoyl]-2-methyl-benzenesulphonamide substantially free of other physical forms, which physical form has an infra-red spectrum (0.5 percent in KBr) having sharp peaks at 1690, 1530, 1490, 1420, 1155, 1060, 862 and 550cm-1, and at least 1 percent by weight of polyvinylpyrrolidone. If the total content of both N-[4-[5-(cyclopentyloxycarbonyl)-amino-1-methylindol-3-yl- -methyl]-3-methoxybenzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone present in said composition is lower than 100 percent by weight parts, the residual has the form of at least one pharmaceutically acceptable carrier and/or one pharmaceutically acceptable auxiliary component. There is further disclosed a process for the preparation of this pharmaceutical composition and an intermediate usable in said process. The composition is useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.</p> |
